EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

BACKGROUND: Arterial hypertension is highly prevalent but poorly controlled. Blood pressure (BP) reduction substantially reduces cardiovascular morbidity and mortality. Recent randomized, double-blind clinical trials demonstrated that azilsartan medoxomil (AZM) is more effective in reducing BP than...

Descripción completa

Detalles Bibliográficos
Autores principales: Gitt, Anselm K, Baumgart, Peter, Bramlage, Peter, Mahfoud, Felix, Potthoff, Sebastian A, Senges, Jochen, Schneider, Steffen, Buhck, Hartmut, Schmieder, Roland E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706336/
https://www.ncbi.nlm.nih.gov/pubmed/23819631
http://dx.doi.org/10.1186/1471-2261-13-46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706336/
https://www.ncbi.nlm.nih.gov/pubmed/23819631
http://dx.doi.org/10.1186/1471-2261-13-46

Ejemplares similares